| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008249 Proteins with high immunoreactivity and method for their production |
| 01/13/2011 | CA2767442A1 Antibody having anti-cancer activity |
| 01/13/2011 | CA2766996A1 Humanised antibodies to toll-like receptor 2 and uses thereof |
| 01/13/2011 | CA2766861A1 In vivo tumor vasculature imaging |
| 01/13/2011 | CA2766856A1 Detection and visualization of the cell cycle in living cells |
| 01/13/2011 | CA2766747A1 Tlr3 binding agents |
| 01/13/2011 | CA2766737A1 Diagnosis and treatment of autoimmune demyelinating diseases |
| 01/13/2011 | CA2766608A1 Bi-specific digoxigenin binding antibodies |
| 01/13/2011 | CA2766166A1 Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
| 01/13/2011 | CA2765478A1 Stabilized immunoglobulin constant domains |
| 01/13/2011 | CA2765090A1 A complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent |
| 01/12/2011 | EP2273419A1 Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| 01/12/2011 | EP2273273A1 Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease |
| 01/12/2011 | EP2273266A1 Parasporin-1 receptor and use thereof |
| 01/12/2011 | EP2272957A2 Bitter taste receptors |
| 01/12/2011 | EP2272951A1 Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| 01/12/2011 | EP2272874A1 Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| 01/12/2011 | EP2272873A2 Antibodies against insulin-like growth factor I receptor and uses thereof |
| 01/12/2011 | EP2272872A1 Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof |
| 01/12/2011 | EP2272870A1 Process for manufacturing immunoglobulins for intravenous administration and other immunoglobulin-like products |
| 01/12/2011 | EP2272869A2 Angiopoietin-2 specific binding agents |
| 01/12/2011 | EP2272868A2 Combination therapy for B cell disorders |
| 01/12/2011 | EP2272566A2 Humanisation of antibodies |
| 01/12/2011 | EP2272565A2 Prevention of thrombus formation and/or stabilization |
| 01/12/2011 | EP2272539A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 01/12/2011 | EP2272533A1 Soluble FcyR fusion proteins and methods of use thereof |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272501A1 Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| 01/12/2011 | EP2272497A2 Methods Of Increasing Lymphatic Function |
| 01/12/2011 | EP2271758A2 Sequence diversity generation in immunoglobulins |
| 01/12/2011 | EP2271674A2 Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders |
| 01/12/2011 | EP2271673A2 Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/12/2011 | EP2271672A2 Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof |
| 01/12/2011 | EP2271671A2 Tnf-alpha inhibitors for treating bone loss |
| 01/12/2011 | EP2271670A1 Immuno-based botulinum toxin serotype a activity assays |
| 01/12/2011 | EP2271669A1 Antibodies with enhanced adcc function |
| 01/12/2011 | EP2271668A2 Adam-15 antibodies and immunogenic peptides |
| 01/12/2011 | EP2271664A1 Novel sequences of brachyspira, immunogenic composition, methods for preparation and use thereof |
| 01/12/2011 | EP2271365A2 Regulation of fatty acid transporters |
| 01/12/2011 | EP2271364A1 Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
| 01/12/2011 | EP2271363A1 Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase |
| 01/12/2011 | EP2271362A2 Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis |
| 01/12/2011 | EP2271359A2 Camptothecin-binding moiety conjugates |
| 01/12/2011 | EP2044443B1 Peptide antibody depletion and its application to mass spectrometry sample preparation |
| 01/12/2011 | EP2027156B1 Hepatocyte growth factor (hgf) binding proteins |
| 01/12/2011 | EP1880215B1 Compositions and methods for detection of sirolimus |
| 01/12/2011 | EP1865058B1 Anti-cd-20 monoclonal antibody |
| 01/12/2011 | EP1533319B1 Method of detecting perilymphatic fistula |
| 01/12/2011 | EP1465927B1 Bag3 antibodies to be used in research, diagnostics and therapy for cell death-involving diseases |
| 01/12/2011 | EP1302541B1 Method for recognizing bacterial DNA |
| 01/12/2011 | EP1105479B1 Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| 01/12/2011 | EP1003782B1 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/12/2011 | CN1791614B Construct comprising recognition domain of antibody against von Willebrand factor-specific cleaving enzyme |
| 01/12/2011 | CN1714147B Method of obtaining cell lines in a protein-free medium and cell lines thus obtained |
| 01/12/2011 | CN1675245B Monoclonal antibody hPAM4 |
| 01/12/2011 | CN101946003A Anti-adam-15 antibodies and utilization of the same |
| 01/12/2011 | CN101945894A Anti-ofloxacin monoclonal antibody and immunoassay method of ofloxacin using the same |
| 01/12/2011 | CN101945893A Anti-human nkg2d monoclonal antibodies and use thereof |
| 01/12/2011 | CN101945892A Methods and agents for improving targeting of cd138 expressing tumor cells |
| 01/12/2011 | CN101945891A Methods for the treatment of gout |
| 01/12/2011 | CN101945890A Crystallization of anti-cd20 antibodies |
| 01/12/2011 | CN101945667A Therapy of rituximab-refractory rheumatoid arthritis patients |
| 01/12/2011 | CN101942450A Vacuolar Na+/H+ antiporter gene of strong xerophil zygophyllumxanthoxylum, plant expression vector and plant genetic transformation method thereof |
| 01/12/2011 | CN101942443A Novel beta-actin and rps21 promoters and uses thereof |
| 01/12/2011 | CN101942442A Novel beta-actin and rps21 promoters and uses thereof |
| 01/12/2011 | CN101942416A Anti-human cardiac troponin I specific monoclonal antibody and preparation method thereof |
| 01/12/2011 | CN101942415A Hybridoma cell strain and anti-hydrochloric acid clenbuterol monoclonal antibody prepared from hybridoma cell strain |
| 01/12/2011 | CN101942414A Hybridoma cell line and chloramphenicol-resistant monoclonal antibody produced by same |
| 01/12/2011 | CN101942011A Neutralizing epitope of human adenovirus type 3 (HAdV-3) and type 7 (HAdV-7) and application thereof |
| 01/12/2011 | CN101940189A Transgenic trasnchromosomal rodents for making human antibodies |
| 01/12/2011 | CN101565690B Enrofloxacin monoclonal antibody and application |
| 01/12/2011 | CN101270162B Antihuman SCGN monoclone antibody, preparation, application and hybrid tumor cell strain |
| 01/12/2011 | CN101235085B Monoclonal antibody of membrane protein E for resisting West Nile virus and application thereof |
| 01/12/2011 | CN101081863B Lipopolysaccharide conjugated protein and monoclonal antibody and usage |
| 01/11/2011 | US7868150 Nucleic acids encoding T2R taste receptors |
| 01/11/2011 | US7868143 by which blood cells can be stimulated; amount of required mAbs is lower than when using the same mAbs in a solution, which makes the stimulation independent from the presence or the quality of non-T cells carrying Fc-receptors, and which can be prepared in an easier way under GMP conditions |
| 01/11/2011 | US7868142 Protein, method for immobilizing protein, structure, biosensor, nucleic acid, vector and kit for detecting target substance |
| 01/11/2011 | US7868141 Anti-OX40L antibodies |
| 01/11/2011 | US7868140 Human anti-B7RP1 neutralizing antibodies |
| 01/11/2011 | US7868138 mutant green fluorescent protein (GFP) with enhanced fluorescent intensity as compared to wild type Aequorea victoria GFP; use of repeated cycles of mutagenesis, in vivo recombination and selection which allow for the directed molecular evolution in vivo and in vitro of highly complex linear sequences |
| 01/11/2011 | US7868137 Search for cancer markers by a novel screening method |
| 01/11/2011 | US7868136 Search for cancer markers by a screening method |
| 01/11/2011 | US7868134 Immunogenic peptides derived from sclerostin |
| 01/11/2011 | US7867734 Monoclonal antibody for use in treatment and prevention of cell proliferative disorders; tissue targeted therapy |
| 01/11/2011 | US7867725 Bone matrix glycoprotein specific immunoglobulin for use in diagnosing renal injury, cancer, cardiovascular and inflammatory disorders |
| 01/11/2011 | US7867704 for detecting Mycobacterium paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies; for immunization and prevention of mycobacterial animal infections |
| 01/11/2011 | US7867502 Genetic engineered polypeptides; useful candidates in a vaccine against tuberculosis (TB) or diagnostic preparation for TB; vaccine; inhibit mycobacterial virulence |
| 01/11/2011 | US7867497 Monoclonal antibodies to respiratory syncytial virus and uses therefor |
| 01/11/2011 | US7867496 Use of TGF-β antagonists to limit nephrotoxicity of immunosuppressive agents |
| 01/11/2011 | US7867495 for inflammatory diseases such as rheumatoid arthritis; GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor); |
| 01/11/2011 | US7867493 for preventing and treating cancer; kits; Prolactin receptor (PRLR) |
| 01/11/2011 | US7867491 hybrid Fc; useful as a carrier of biologically active molecules |
| 01/11/2011 | US7867475 Using NK gene complex family of type II oligomeric signal transmitting receptor proteins containing C-type lectin-binding domain; increasing tumor necrosis factor alpha production; autoimmune diseases |
| 01/11/2011 | CA2377479C Compositions and methods for preventing transepithelial transmission of hiv |
| 01/11/2011 | CA2286313C Novel ldl-receptor |
| 01/06/2011 | WO2011002931A2 Markers of xmrv infection and uses thereof |
| 01/06/2011 | WO2011002721A1 Non-human mammal model of human hematopoietic cancer |